Navigation Links
Peregrine Pharmaceuticals Presents Promising Antiviral Data at 2009 Chemical and Biological Defense Science & Technology Conference
Date:11/18/2009

the full $44.4 million awarded under the federally funded program, the risk that bavituximab will not achieve broad-spectrum anti-viral effects, the risk that PS-targeting antibodies will not be less susceptible to viral mutations and the risk that the results of clinical trials will not correlate to the preclinical study results. It is important to note that the company's actual results could differ materially from those in any such forward-looking statements. Factors that could cause actual results to differ materially include, but are not limited to, uncertainties associated with completing preclinical and clinical trials for our technologies; the early stage of product development; the significant costs to develop our products as all of our products are currently in development, preclinical studies or clinical trials; obtaining additional financing to support our operations and the development of our products; obtaining regulatory approval for our technologies; anticipated timing of regulatory filings and the potential success in gaining regulatory approval and complying with governmental regulations applicable to our business. Our business could be affected by a number of other factors, including the risk factors listed from time to time in the company's SEC reports including, but not limited to, the annual report on Form 10-K for the year ended April 30, 2009 and the quarterly report on Form 10-Q for the quarter ended July 31, 2009. The company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. Peregrine Pharmaceuticals, Inc. disclaims any obligation, and does not undertake to update or revise any forward-looking statements in this press release.

    Contacts:
    GendeLLindheim BioCom Partners
    Investors                           Media
   '/>"/>
SOURCE Peregrine Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Peregrine Pharmaceuticals Reports Positive Results From Phase II Bavituximab Lung Cancer Trial
2. Peregrine Pharmaceuticals Reports Advances in Bavituximab Clinical Program
3. Peregrine Pharmaceuticals to Present at the Rodman & Renshaw 11th Annual Healthcare Conference
4. Peregrine Pharmaceuticals to Report First Quarter FY 2010 Financial Results
5. Peregrine Pharmaceuticals to Present at the Jesup & Lamont 2009 Growth Stock & National Sales Conference
6. Peregrine Pharmaceuticals Licenses Anti-VEGF Antibodies to Affitech
7. Peregrine Awarded European Patent for Innovative Labeling Technology Featured in New Study in The Journal of Nuclear Medicine
8. Data Presented at Society of Nuclear Medicine 2009 Annual Meeting Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting
10. Clinical Data on Peregrines Bavituximab Cancer Program to Be Discussed in Two Presentations at 2009 ASCO Annual Meeting
11. Peregrine Pharmaceuticals Reports Positive Data in Second Phase II Bavituximab Breast Cancer Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/1/2014)... This report analyzes the worldwide markets for ... following Product Segments: Proteases, Polymerases, Carbohydrases, and ... analyzed are Pharmaceuticals & Diagnostics, Research/Biotechnology, and ... comprehensive analytics for the US, Canada, Japan, ... Annual estimates and forecasts are provided for ...
(Date:9/30/2014)... Using a bio-mimicking analog of one of nature,s ... international research team led by Alejandro Briseno of ... major step in developing long-sought polymer architecture to ... use in electronic devices. , Briseno, with ... others at Stanford University and Dresden University of ...
(Date:9/30/2014)... September 30, 2014 Over the last ... due to rising R&D budgets and increased acceptance of ... growing pharmaceutical and biotechnology industries are also catalyzing the ... filtration market is expected to grow at a strong ... estimated to be worth $2,532.6 million by 2019. The ...
(Date:9/30/2014)... September 30, 2014 Fast, ... of chemistry in documents ChemAxon ... and consulting services for life science research, launches ... generate Markush structures from documents. Markush ... property, however generating and understanding Markush structures is ...
Breaking Biology Technology:Global Specialty Enzymes Industry 2Global Specialty Enzymes Industry 3Global Specialty Enzymes Industry 4Global Specialty Enzymes Industry 5Global Specialty Enzymes Industry 6Global Specialty Enzymes Industry 7Global Specialty Enzymes Industry 8Global Specialty Enzymes Industry 9Global Specialty Enzymes Industry 10Global Specialty Enzymes Industry 11Global Specialty Enzymes Industry 12Global Specialty Enzymes Industry 13Global Specialty Enzymes Industry 14Global Specialty Enzymes Industry 15Global Specialty Enzymes Industry 16Global Specialty Enzymes Industry 17Global Specialty Enzymes Industry 18Global Specialty Enzymes Industry 19Global Specialty Enzymes Industry 20Global Specialty Enzymes Industry 21Global Specialty Enzymes Industry 22Global Specialty Enzymes Industry 23Global Specialty Enzymes Industry 24Global Specialty Enzymes Industry 25Global Specialty Enzymes Industry 26Blades of grass inspire advance in organic solar cells 2Blades of grass inspire advance in organic solar cells 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 2Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 3Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 4Global Laboratory Filtration Market To See 7.0% CAGR to 2019 Says a Research Report Available at ReportsnReports.com 5ChemAxon Introduces ChemCurator for Chemical Information Extraction and Markush Structure Creation 2
... to lead ... expansion, FORT WORTH, ... today the appointment of,Michael J. "Mike" Tansey as Chief Executive Officer., ... is poised to,enter a period of accelerated growth," said Mr. Tansey. "The ...
... Chatterjee Brings Over Thirteen Years of Capital Markets ... Experience to AOBO -,- New Role Emphasizes Strategic Growth Plan and Capital ... ... Inc. (NYSE: AOB ) ("AOB" or "the Company"), a pharmaceutical,company dedicated to improving health ...
... a Hearing -, MONTVALE, N.J., June 9 ... on June 6, 2008 it received a,letter from the ... has not regained compliance with the $1.00 bid,price requirement ... to delisting from The NASDAQ Global Market, unless the ...
Cached Biology Technology:onTargetjobs Announces Appointment of Michael Tansey as New CEO 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 2American Oriental Bioengineering Appoints Anindya Chatterjee to Chief Strategy Officer 3Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 2Memory Pharmaceuticals Receives Anticipated NASDAQ Staff Determination Letter 3
(Date:9/30/2014)... release is available in German . ... among the most expensive foods in the world. Because they ... them. But the distinctive smell of truffles is not only ... scientists under the direction of the Goethe University Frankfurt have ... by soil bacteria which are trapped inside truffle fruiting bodies. ...
(Date:9/30/2014)... some hope: A new research report published in October ... , explains how scientists developed a synthetic version of ... development in human and mouse eggs similar to the ... during fertilization. , "We believe that the results of ... understanding of human fertilization by providing a precise answer ...
(Date:9/30/2014)... -- Winners of The Economist,s prestigious Innovation awards 2014 ... place at the JW Marriott Hong Kong on Friday, October 10 ... their experiences and the lessons those hold for others. The awards, ... the past decade, will be presented at a ceremony in ... will be the first time the ceremony has come to ...
Breaking Biology News(10 mins):On the trail of the truffle flavor 2Synthetic sperm protein raises the chance for successful in vitro fertilization 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 2Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 3Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 4Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 5Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 6Hear from The Economist's 2014 Innovation Award Winners at Innovation Summit on October 10th in Hong Kong 7
... over global warming and instead reduce fossil-fuel use for the ... scientists, one from the University of Washington and one from ... in the current issue of the journal Nature ... supply will trump the environment as a reason to curb ...
... Irvine, Calif., Jan. 26, 2012 Location matters for ... UC Irvine and Wesleyan University. Findings suggest that chickadees and ... as the characteristics of their wriggly prey. Unfortunately for ... can dramatically boost their own risk of becoming food. Study ...
... for breast cancer research as well as basic cell ... Lawrence Berkeley National Laboratory (Berkeley Lab) have discovered a ... ability of breast cells to form the spherical structures ... which the researchers call "CAMo," for coherent angular motion, ...
Cached Biology News:Commentary in Nature: Can economy bear what oil prices have in store? 2Commentary in Nature: Can economy bear what oil prices have in store? 3For the birds 2Berkeley Lab researchers discover critical rotational motion in cells 2Berkeley Lab researchers discover critical rotational motion in cells 3Berkeley Lab researchers discover critical rotational motion in cells 4
MOUSE ANTI SIMIAN VIRUS 5 Immunogen: Simian virus 5...
... Dog Serum-Mixed Breed • Dog serum is collected ... one year of age Available Anticoagulants: ... (Na) N-06: K2EDTA N-08: ... N-03: Alsevers N-05: ACD ...
Ready-to-use; 40mg/ml X-Gal and 32mg/ml IPTG...
Whole blood is collected from canines (any breed, either sex), refrigerated within 6 hours, processed within 24 hours and frozen at -20C....
Biology Products: